Australia markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.99-0.53 (-1.25%)
At close: 04:00PM EDT
42.00 +0.01 (+0.02%)
After hours: 07:57PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
524,070
396,591
75,422
66,563
250,646
Cost of revenue
70,910
58,510
5,636
5,200
25,050
Gross profit
453,160
338,081
69,786
61,363
225,596
Operating expenses
Research development
329,061
354,387
387,236
420,869
299,921
Selling general and administrative
528,227
500,815
277,163
176,771
139,401
Total operating expenses
857,288
855,202
664,399
597,640
439,322
Operating income or loss
-404,128
-517,121
-594,613
-536,277
-213,726
Interest expense
29,019
29,581
32,626
13,241
29,937
Total other income/expenses net
-949
-727
-33,178
-196,902
-103,530
Income before tax
-415,253
-526,496
-651,503
-746,002
-343,029
Income tax expense
2,020
2,132
669
352
1,845
Income from continuing operations
-417,273
-528,628
-652,172
-746,354
-344,874
Net income
-417,273
-528,628
-652,172
-746,354
-344,874
Net income available to common shareholders
-417,273
-528,628
-652,172
-746,354
-344,874
Basic EPS
-5.23
-4.45
-6.15
-8.84
-4.59
Diluted EPS
-5.23
-4.45
-6.15
-8.84
-4.59
Basic average shares
116,028
118,678
106,114
84,421
75,163
Diluted average shares
116,028
118,678
106,114
84,421
75,163